Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$634.00
-3.00 (-0.46%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 19%
FCF escenarios
weak_data · normalized FCF $4.5B · quality 37.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$18.4B
P/E
N/A
•EV/EBITDA
3.2x
↓ROE
27.7%
↑Gross Margin
78.4%
↑Debt/Equity
1.46
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+10.0%
FCF CAGR
-7.8%
FCF margin
7.3%
FCF / Net income
1.41x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.15B · net income $3.21B · FCF $4.51B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.15B | $62.15B | $68.57B | $60.19B | $46.75B |
| Net Income | $3.21B | $3.21B | $3.08B | $-374.0M | $3.84B |
| EBITDA | $6.00B | $6.00B | $4.14B | $1.97B | $5.96B |
| EPS | — | — | 106.70 | -12.89 | 132.14 |
| Gross Margin | 78.4% | 78.4% | 80.6% | 79.9% | 85.0% |
| Operating Margin | 8.2% | 8.2% | 5.3% | 1.8% | 12.1% |
| Net Margin | 5.2% | 5.2% | 4.5% | -0.6% | 8.2% |
| Balance Sheet | |||||
| Debt/Equity | 1.46 | 1.46 | 2.09 | 2.38 | 0.58 |
| Current Ratio | 1.03 | 1.03 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $4.51B | $4.51B | $5.72B | $-6.54B | $5.76B |
| Returns | |||||
| ROE | 27.7% | 27.7% | 32.0% | -5.3% | 45.4% |
| Valuation | |||||
| P/E | — | — | 15.84 | — | 21.21 |
| EV/EBITDA | 3.17 | 3.17 | 12.72 | 25.14 | 12.85 |
| P/B | 1.54 | 1.54 | 5.07 | 5.87 | 9.63 |
| Growth & Yield | |||||
| Revenue Growth | -9.4% | -9.4% | 13.9% | 28.7% | — |
| EPS Growth | — | — | 927.8% | -109.8% | — |
| Dividend Yield | 3.9% | 3.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.0%
Start / end P/E
n/dx → n/dx
EPS bridge
106.70 → n/d
Residual
-30.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.